Form D · Biotechnology
Convergent Therapeutics, Inc.
Cambridge, MA · CIK 0001978126
Offering snapshot reported Aug 13, 2024 · SEC filing
- Reported sold
- $22.2M Offering amount: $40M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 13, 2024 | Initial | $22,222,220 | No comparison | 1 | SEC filing |
| May 22, 2023 | Initial | $29,170,704 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521383
Source: Form D, filed Aug 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Neil Bander | Director, Executive |
| Alexander Brown | Executive |
| Philip Kantoff | Director, Executive |
| Jake Simson | Director |
| Eric Sullivan | Executive |
| Jim Trenkle | Director |
| Tal Zaks | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Broadway 14 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142